• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2333-6439
    Volume 5, Issue 3
    Case Report
    Saurabh V Phadnis, Melanie Powell, Ayshea Hameeduddin, Naveena Singh, and Elly Brockbank
    Low grade endometroid endometrial carcinoma has a low recurrence rate. We report diagnosis and management of an unusual case of late recurrence at dual site.
    Van Keirsbilck Joachim*, Serkei Elvira, Vanwalleghem Lieve, Vanderbeke Ilse, De Catte Luc, and Decaluwe Wim
    Teratoma is a rare tumor of the umbilical cord. Teratomas arise from totipotent embryonic cells from all three germinal layers. Teratomas are polymorphic in their presentation. Few have immature elements. Half of the cases present associated anomalies, with omphalocele being the most frequent one. Due to mechanic compression and/or change in fetal hemodynamics teratomas may lead to an increase in perinatal morbidity and mortality.
    Our case presents a 30-year-old woman with a cystic mass of the umbilical cord of 4,7 cm at 13 weeks pregnancy. Serial high-resolution ultrasound examination and Color Doppler imaging was used to monitor the expanding mass until a maximal diameterof 21 x 20 x 17 centimeterswerereached. Fetal developmentand well-being remained unremarkably. A cesarean section at 29 weeks and 6 days was imperative due to the worsening maternal condition related to the severely distended abdomen. In order to facilitate the delivery an in utero drainage of the cystic mass was performed. Pathological and histological examinations of the mass revealed an immature teratoma dominantly composed of neuroglial tissue.
    Short Communication
    Geraldine Cheyana Ranasinghe, Melissa Piliang, and Wilma Bergfeld*
    Studies on the pathophysiology and comorbidities associated with alopecia areata (AA) are limited. The purpose of this study was to determine the prevalence of androgen excess in AA and its subtypes, in relation to demographics and comorbidities. Medical records of 1,587 Patchy AA, AT, AU, and ophiasis patients seen in the Department of Dermatology at the Cleveland Clinic Foundation in Ohio between 2005 and 2015 were reviewed. Out of this cohort, 220 patients met the inclusion criteria. Androgen excess was identified in 42.5% (n=96) of the 220 patients with AA and all subtypes (p<0.001). The androgen excess group was significantly more likely to present with adult acne, hirsutism, PCOS, and/or ovarian cysts (p<0.001). This study was limited by being retrospective. Our study demonstrated that AA is associated with androgen excess.
    Review Article
    Kathy Pan*, JuhuaLuo, Reina Haque, Garnet L. Anderson, and Rowan T. Chlebowski
    Breast cancer and endometrial cancer share several risk factors, including age, obesity and higher endogenous estrogen levels. As a result, these two cancers may be amenable to common risk reduction strategies. This possibility was evaluated in studies undertaken in the Women’s Health Initiative (WHI) cohort and in the Kaiser Permanente Southern California (KPSC) integrated health plan. In the WHI Observational Study, intentional weight loss was associated with a significant reduction in endometrial cancer risk (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.42–0.86). In the KPSC cohort of women with breast cancer, as might be expected given the known risk profile of tamoxifen, aromatase inhibitor use was associated with significantly lower endometrial cancer risk compared to tamoxifen use (HR 0.52, 95% CI0.31–0.87). Compared to the no endocrine therapy group, aromatase inhibitor users had a trend towards fewer endometrial cancers (HR 0.71, 95% CI 0.37–1.35).As the aromatase inhibitors exemestane and anastrozole have been demonstrated to reduce breast cancer incidence in full scale primary prevention trials, findings fromthe studies outlined in this review suggest two potential strategies for reducing both breast cancer and endometrial cancer risk, especially in overweight and obese women who are most likely to develop these diseases.
    Short Note
    Dominic Adam Worku*
    Ovarian cancer is the 5th most common cancer in females, with the highest mortality of any gynaecological malignancy today [1,2]. Despite modern advances in treatment over the last 40 years, up to 70% of diagnosed females present with late stage disease in whom the UK 5-year survival remains unchanged [3,4]. Unlike other female cancers including endometrial, breast and cervical cancer, which can be diagnosed early through appropriate clinical examination and biopsy, ovarian cancers can only be diagnosed by invasive investigations such as omental biopsy, laparoscopy and laparotomy [2,4].
  • Current Issue Highlights
  • JSciMed Central welcomes back astronaut Scott Kelly and cosmonaut Mikhail Kornienko.

    Wonder Women Tech not only disrupted the traditional conference model but innovatively changed the way conferences should be held.

    JSciMed Central Peer-reviewed Open Access Journals
    10120 S Eastern Ave, Henderson,
    Nevada 89052, USA
    Tel: (702)-751-7806
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: mjog@jscimedcentral.com
    1455 Frazee Road, Suite 570
    San Diego, California 92108, USA
    Tel: (619)-373-8720
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: mjog@jscimedcentral.com
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.